The anti-angiogenic property of vitamin E compounds, with particular emphasis on tocotrienol, has been investigated in vitro. Tocotrienol, but not tocopherol, inhibited both the proliferation and tube formation of bovine aortic endothelial cells, with dtocotrienol appearing the highest activity. Also, dtocotrienol reduced the vascular endothelial growth factor-stimulated tube formation by human umbilical vein endothelial cells. Ourˆndings suggest that tocotrienol has potential use as a therapeutic dietary supplement for minimizing tumor angiogenesis.
Key words: angiogenesis inhibitor; cancer; tocopherol; tocotrienol; vitamin E Vitamin E occurs in nature as at least eight diŠer-ent isoforms that include a-, b-, g-, and d-isomers of both tocopherol and tocotrienol (Fig. 1 ). Humans and animals are unable to synthesize vitamin E and therefore must obtain the isomers from plant sources. Tocopherol is abundantly present in staple foods such as nuts and common vegetable oils, whereas tocotrienol is only a minor constituent of plants with high levels occurring in palm oil, cereal grains, and rice bran.
A major physiological activity of vitamin E is its well-deˆned antioxidant action and protective eŠect against lipid peroxidation in biological membranes, 1, 2) with a-tocopherol having the highest biological activity among the vitamin E isoforms. 3) However, a recent study suggested that tocotrienol may be a better antioxidant than tocopherol 4) as it was found to inhibit 3-hydroxy-3-methylglutarylcoenzyme A reductase activity and thereby reduce cholesterol synthesis. 5) Two other studies reported tocotrienol also had potential anti-thrombotic and anti-tumor eŠects. 6, 7) Taken together, theseˆndings indicate tocotrienol may be an eŠective agent in the prevention and W or treatment of cardiovascular disease and cancer.
Anti-angiogenic therapy has recently become established as a strategy for cancer prevention. 8) As oxidative stress is an important factor in angiogenesis, 9, 10) it is possible that established antioxidants such as vitamin E may minimize the formation of new blood vessels from existing vascular beds. This process normally involves a series of steps including endothelial cell activation and breakdown of the basement membrane, followed by migration, proliferation, and tube formation of the endothelial cells.
11) The purpose of this study was to determine the eŠects of vitamin E, especially tocotrienol, on the in vitro angiogenesis by measuring endothelial cell proliferation and tube formation.
Bovine aortic endothelial cells (BAEC) were obtained from Dainippon Pharmaceutical Co., Ltd. (Osaka, Japan). Cells were cultured on 60-mm collagen-coated culture dishes in 5 ml of minimum essential medium eagle (MEM; Sigma, St. Louis, MO, USA) containing 10z fetal bovine serum (FBS), 100 units W ml penicillin and 100 mg W ml streptomycin at 379 C in 5z CO2. The cells were used after 8 to 12 doublings of the population. Stock solutions of vitamin E homologues (Fuji Chemical Industry Co., Ltd., Toyama, Japan) dissolved in ethanol were prepared. Immediately before use, the stock solutions were diluted in culture medium to give aˆnal ethanol concentration of 0.1z (v W v). Control cul- tures received vehicle alone (ethanol) in every experiment.
Proliferation of BAEC was assessed by the WST-1 method. 12, 13) Brie‰y, the cells were seeded onto 96-well collagen coated culture plates at a density of 2× 10 3 cells W well in 100 ml of MEM containing 10z FBS. After incubation for 24 h at 379 C, the cells were placed in 100 ml of fresh MEM containing 2z FBS with a range of concentrations of either tocopherol or tocotrienol. Twenty-four hours later, 10 ml of WST-1 solution was added to each well in order to evaluate cell proliferation. After 3 h of incubation, cell proliferation was measured using a microplate reader (Model 550, Bio-Rad, Tokyo, Japan) at a wavelength of 450 nm and a reference wavelength of 655 nm. Tube formation was assessed using a threedimensional culture method 14) in which BAEC (1× 10 5 cells W well) were pre-incubated for 24 h on 12-well collagen coated culture plates in 1.5 ml MEM containing 10z FBS. After removal of the medium, the cells were overlaid with 0.5 ml of collagen gel solution consisting of 8 volumes of Vitrogen collagen, 1 volume of ten-times concentrated MEM and 1 volume of 0.1 M NaOH. A 1.5-ml portion of fresh MEM containing 2z FBS and various concentrations of vitamin E isomers were added to each well followed by incubation for 72 h. The cells were then examined for morphological changes and photographed with the length of tube formation measured with the Adobe Photoshop version 5.5 (Adobe Systems Inc., USA).
In this study, before the evaluation of anti-angiogenic activity, the eŠects of tocotrienol and tocopherol on BAEC proliferation was testedˆrst. Tocotrienol in the low micromolar range inhibited all BAEC proliferation that was assessed by WST-1 (Fig. 2) , but the inhibitory potency of each tocotrienol isomer varied markedly as the following order; d-Àb-Àg-Àa-tocotrienol. On the other hand, tocopherol did not aŠect BAEC proliferation even though increasing their concentration at 100 mM (data not shown). These results suggested that tocotrienol may be a more bioactive compound than tocopherol, and that tocotrienol has a potential for acting as an angiogenesis inhibitor. Such quite diŠerent eŠects of tocotrienol and tocopherol on cell proliferation is consistent with previous reports using mouse mammary epithelial cells 15) and human breast cancer cells. 16) According to the inhibitory eŠect and mechanism of vitamin E on cell proliferation, further studies would be needed. From these results, vitamin E in the concentration range of 1-30 mM for tocotrienol and of 1-100 mM for tocopherol was chosen for the next tube formation assay to evaluate their anti-angiogenic properties.
Potting tocotrienol (1-30 mM) through the tube formation assay, we conˆrmed that all the isomers signiˆcantly reduced the width and the length of endothelial tubes of BAEC (Fig. 3) . The ranked order of this inhibitory eŠect was d-Àb-Àg-Àa-tocotrienol. It is important to note that the inhibition of BAEC tube formation by tocotrienol occurred at a lower concentration than that required for inhibiting the cell growth. For example, 15 mM a-tocotrienol resulted in an approximately 60z inhibition of tube formation (Fig. 3) , but did not inhibit cell growth (Fig. 2) . In contrast with theˆndings with tocotrienol, a-, b-, and g-tocopherol failed to inhibit tube formation of BAEC at physiological concentrations of below 100 mM (data not shown). However, d-tocopherol at a concentration of 100 mM was associated with minor suppression of BAEC tube formation. Theseˆndings (Figs. 2, 3 ) indicated that the anti-angiogenic eŠect of tocotrienol is higher than that of tocopherol. Structurally, tocopherol and tocotrienol are distinguished by their side chains and it has been demonstrated that the unsaturated side chain of tocotrienol allows it to pass through cell membranes more e‹ciently and at a faster rate than the saturated side-chain of tocopherols.
3) It is possible therefore that the greater anti-angiogenic eŠect of tocotrienols may be due, in part, to their eŠective incorporation into BAEC.
Since, in this study, d-tocotrienol would be a most potent anti-angiogenic compound among vitamin E, we then investigated the eŠects of the compound on the vascular endothelial growth factor (VEGF)-stimulated tube formation of human umbilical vein endothelial cells (HUVEC), by using an Angiogenesis kit (Kurabo Industries, Ltd., Osaka, Japan). The assay procedure was done according to the manufacturer's instructions. When HUVEC co-cultivated withˆbroblasts were cultured in the presence of 10 ng W ml of VEGF for 11 days, the increases of the tube-like structure was conˆrmed (Fig. 4) . Simultane- ously added d-tocotrienol (1 mM) with VEGF to the medium signiˆcantly reduced the VEGF-stimulated tube formation by HUVEC (Fig. 4) . VEGF is an endothelial cell-speciˆc mitogen and an angiogenesis inducer released by a variety of tumour cells, and is known to play an important role in a number of pathological events such as tumor angiogenesis. 8) Hence, d-tocotrienol revealed higher anti-angiogenic eŠect (Fig. 4) , presumably due to inhibiting the signal transduction pathway initiated by VEGF.
Currently there is considerable work being undertaken to screen potentially anti-angiogenic compounds. The dietary constituents curcumin, 17) ‰avo-noids, 18, 19) selenium, 20) N-acetylcysteine, 21) vitamin D3 22) and several fatty acids including eicosapentaenoic acid 23) have all been shown to inhibit angiogenesis in vitro and W or in vivo. As shown in this study, tocotrienol may represent a member of a new class of dietary-derived anti-angiogenic compounds. Angiogenic inhibitors derived from natural products HUVEC co-cultured withˆbroblasts were incubated in medium containing VEGF (10 ng W ml) with several concentrations of dtocotrienol. After 11 days, the cells were made visible by CD31 antibody and photographed (A), and the length of the tube was measured (B). Data expressed as mean±SD; n＝4. * Cells were died, and therefore the tube length could not be measured. T3, tocotrienol.
have an advantage in that they are non-toxic at physiological doses, can be given orally, and can be easily obtained or manufactured.
In conclusion, tocotrienol signiˆcantly inhibited the proliferation and tube formation of BAEC as well as VEGF-induced tube formation by HUVEC. Among the vitamin E group, only tocotrienol had a signiˆcant anti-angiogenic eŠect.
